Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

Thousands of lawsuits cite studies linking paraquat to Parkinson’s disease. The EPA says the evidence doesn't warrant a ban ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

The US Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in ...

Company to host a webcasttoday at 8:30 a.m. Eastern TimeNEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the ...

And some researchers hoped that the drugs could also help with some of the most difficult diseases to treat — those of the brain, like Parkinson’s. But now, at least for Parkinson’s ...

ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s diseaseONAPGO is a wearable subcutaneous infusion ...